Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.8%

88 terminated/withdrawn out of 896 trials

Success Rate

86.1%

-0.4% vs industry average

Late-Stage Pipeline

9%

82 trials in Phase 3/4

Results Transparency

38%

207 of 547 completed trials have results

Key Signals

142 recruiting207 with results55 terminated33 withdrawn

Enrollment Performance

Analytics

N/A
354(54.8%)
Phase 2
97(15.0%)
Phase 1
95(14.7%)
Phase 4
48(7.4%)
Phase 3
34(5.3%)
Early Phase 1
18(2.8%)
646Total
N/A(354)
Phase 2(97)
Phase 1(95)
Phase 4(48)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (896)

Showing 20 of 896 trials
NCT05160948Completed

Change in Knowledge After Receiving Personal Air Pollution Results

Role: lead

NCT04857255Not ApplicableCompleted

Technology-assisted Language Intervention (TALI)

Role: lead

NCT02675959Phase 2Recruiting

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Role: collaborator

NCT01764529Completed

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Role: collaborator

NCT03235414Not ApplicableCompleted

Normal Liver Stiffness by MR Elastography

Role: lead

NCT04925375Phase 2Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Role: lead

NCT07718464Recruiting

FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids

Role: lead

NCT07712835Completed

ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis

Role: collaborator

NCT07708714Phase 1Recruiting

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

Role: lead

NCT06615375Phase 2Active Not Recruiting

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Role: collaborator

NCT05898022Phase 4Completed

Pragmatic Research on Diuretic Management in Early BPD Pilot

Role: lead

NCT07666048Not Yet Recruiting

Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease

Role: lead

NCT07699107Phase 4Not Yet Recruiting

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

Role: collaborator

NCT07606131Not ApplicableNot Yet Recruiting

Testing a Registry-Based Strategy (ACT+) to Reduce Loss to Follow-Up in Rheumatic Heart Disease Screening in Uganda

Role: lead

NCT06110520Not ApplicableTerminated

Violet Light for the Suppression of Myopia

Role: lead

NCT06560242Not ApplicableRecruiting

Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant

Role: lead

NCT05803343Not ApplicableRecruiting

Evaluating Additive Effects of Including Canines in Regulating Together

Role: lead

NCT07676539Not ApplicableActive Not Recruiting

Adapting the STRW Intervention for Adolescents and Young Adults With Epilepsy (ARGOS)

Role: lead

NCT04717427Completed

Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome

Role: collaborator

NCT07684417Not ApplicableNot Yet Recruiting

Impact of Short and Mistimed Sleep on Adolescents With ADHD: The Adolescent Attention and Circadian Timing Study

Role: lead